Pharma major Lupin on Wednesday said it has launched generic immune-suppressant Tacrolimus capsules in the American market after its alliance conglomerate Concord Biotech received an approval for the product from the United State’s health regulator.

The company has launched Tacrolimus capsules USP in the strengths of 0.5 mg, 1 mg, and 5 mg, after Concord Biotech Ltd received an approval for its abbreviated new drug application (ANDA) from the USFDA,  Lupin said in a regulatory filing.

Let us know, the capsules are generic versions of Astellas Pharma US Inc's Prograf capsules in the same strengths. According to IQVIA MAT September 2020 data, Tacrolimus capsules USP of 0.5 mg, 1 mg, and 5 mg had an annual sales of around USD 303 million in the US. The capsules are indicated for the prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant, liver transplant, and heart transplant, and in pediatric patients receiving allogeneic liver transplants, in combination with other immune-suppressants, the pharma major said.

Reacting to the development,  Shares of Lupin Ltd quoted an intraday high level at 907.30 per scrip on the NSE, on Wednesday.

REC LTD deposits penalty amount to SEBI (IPEF) for inadvertent trade

All India Bank Employees' Association to join countrywide strike on Thursday

HDFC Bank Valuation beats Rs 8 Lakh Crore